Viewing Study NCT03510533


Ignite Creation Date: 2025-12-25 @ 2:49 AM
Ignite Modification Date: 2026-01-01 @ 4:29 AM
Study NCT ID: NCT03510533
Status: UNKNOWN
Last Update Posted: 2018-04-27
First Post: 2018-04-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Validation of the Concept of the Autoantibodies Directed Against the Neuropeptides Involved in Food Intake Regulation on the Incidental Cases of Eating Disorders
Sponsor: University Hospital, Rouen
Organization:

Study Overview

Official Title: Validation of the Concept of the Autoantibodies Directed Against the Neuropeptides Involved in Food Intake Regulation on the Incidental Cases of Eating Disorders
Status: UNKNOWN
Status Verified Date: 2018-04
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: EDILS-AutoAC
Brief Summary: This study should lead to the validation of the concept of the autoAc directed against the neuropeptides involved in food intake regulation.
Detailed Description: Eating disorders are a public health issue. It has been recently reported the importance of immune system modifications in eating disorders physiopathology, involving autoantibodies directed against neuropeptides regulating food intake. A recent study of laboratory INSERM 1073 showed the existence of an intestinal bacterial protein exhibiting structural similarities with α-MSH: ClpB. The autoAc directed against the latter also react with α-MSH because of these similarity of structures, thus leading to a potential digestive origin of these autoAc. To consolidate this new etiopathogenic assumption, a large clinical study is necessary with analysis of patients autoAc profiles. a monocentric study with inclusion of 240 patients over 2 years and 80 healthy volunteers is proposed.

This study should lead to the validation of the concept of the autoAc directed against the neuropeptides involved in food intake regulation. Nutritional modulations (probiotic, amino-acid…) could constitute an interesting therapeutic perspective in the future.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2017-A00875-48 OTHER Agence Nationale de Sécurité du médicament et des produits de Santé View